Q
Quant'AbondanceL'abondance, quantifiée.

Actualités

Uniquement les titres à fort signal - événements macro, résultats, M&A, régulation. Listicles et clickbait d'analystes filtrés par défaut. Rafraîchi toutes les heures.

25,542 signal articles · 32 in last 24h · 122,390 total before filter · latest 58m ago
32last 24h
1246last 7d
208● bullish (7d)
149● bearish (7d)
205publishers
AllMacro211Earnings426M&A97Regulatory24Product9Analyst10
✕ clear all filterssentiment: bullishSentiment:bullishneutralbearish✓ showing all (incl. clickbait)
3 Reasons to Avoid ALGN and 1 Stock to Buy Instead
StockStory54d agobullish
3 Reasons to Avoid ALGN and 1 Stock to Buy Instead

Over the past six months, Align Technology has been a great trade, beating the S&P 500 by 5.5%. Its stock price has climbed to $177.15, representing a healthy 12.2% increase. This was partly thanks to its solid quarterly results, and the performance may have investors wondering how to approach the situation.

Palo Alto Networks Surges 9%, CrowdStrike Rises 7%, Okta Gains 5%: Can the Cybersecurity Rally Justify Its Valuations?
24/7 Wall St.54d agobullish
Palo Alto Networks Surges 9%, CrowdStrike Rises 7%, Okta Gains 5%: Can the Cybersecurity Rally Justify Its Valuations?

Shares of Palo Alto Networks (NASDAQ:PANW) are up 9% to $331.91 at midday Monday, leading a sharp rally across cybersecurity platform leaders. CrowdStrike (NASDAQ:CRWD) stock is up 7% to $747.84, and Okta (NASDAQ:OKTA) stock is up 5% to $130.23. The synchronized move caps a powerful run for the group. Year to date (YTD), Palo Alto ... Palo Alto Networks Surges 9%, CrowdStrike Rises 7%, Okta Gains 5%: Can the Cybersecurity Rally Justify Its Valuations?

HIVE Digital (HIVE): The Best High Growth Penny Stock to Buy
Insider Monkey54d agobullish
HIVE Digital (HIVE): The Best High Growth Penny Stock to Buy

HIVE Digital Technologies Ltd. (NASDAQ:HIVE) is one of the 8 High Growth Penny Stocks to Buy. On June 25, 2026, HIVE Digital Technologies Ltd. (NASDAQ:HIVE) announced that HIVE Bermuda 2026, its wholly-owned subsidiary, intends to offer $100M aggregate principal amount of 0% exchangeable senior notes due 2031. The private offering is subject to market conditions […]

RBC Capital Keeps Outperform Rating on Carvana (CVNA)
Insider Monkey54d agobullish
RBC Capital Keeps Outperform Rating on Carvana (CVNA)

Carvana Co. (NYSE:CVNA) is one of the 10 Interest Rate Sensitive Stocks to Buy Now. On June 12, 2026, RBC Capital lowered its price target on Carvana Co. (NYSE:CVNA) to $85 from $92 and kept an Outperform rating. RBC Capital updated its retail unit cohort model to gauge market share gain expectations embedded in Street […]

AvalonBay (AVB): The Best Interest Rate Sensitive Stock to Buy Now
Insider Monkey54d agobullish
AvalonBay (AVB): The Best Interest Rate Sensitive Stock to Buy Now

AvalonBay Communities, Inc. (NYSE:AVB) is one of the 10 Interest Rate Sensitive Stocks to Buy Now. On June 16, 2026, Truist raised its price target on AvalonBay Communities, Inc. (NYSE:AVB) to $202 from $201 and kept a Buy rating. Truist adjusted its model with expectations for 1.3% year-over-year same-store revenue growth in 2026 and 3.9% […]

Axon Soars on Trump Stock Purchase Highlighting Insider Trading Issues
24/7 Wall St.54d agobullish
Axon Soars on Trump Stock Purchase Highlighting Insider Trading Issues

Markets have become increasingly sensitive to any headline that hints at government spending or political influence. Defense contractors, AI companies, and cybersecurity firms can all move sharply on a single news report, even when the underlying information isn’t actually new. That happened again today after CNBC reported that President Trump bought between $1 million and ... Axon Soars on Trump Stock Purchase Highlighting Insider Trading Issues

AbbVie (ABBV) Wins Backing For Two RINVOQ Skin Disease Uses In Europe
Simply Wall St.54d agobullish
AbbVie (ABBV) Wins Backing For Two RINVOQ Skin Disease Uses In Europe

AbbVie (NYSE:ABBV) received positive opinions from the European Medicines Agency's CHMP for RINVOQ in severe alopecia areata and non-segmental vitiligo. If approved, RINVOQ could become the first systemic therapy for non-segmental vitiligo in Europe. The new indications target areas with high unmet medical need in dermatology and immunology. AbbVie has been active across immunology, gastroenterology and virology, and RINVOQ is already a core asset in its portfolio. These fresh CHMP...